Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at - Antibody - Document - PDFSEARCH.IO

First Page	Meta Content
	Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at Add to Reading List Document Date: 2017-10-03 19:39:52 Open Document File Size: 113,31 KB Share Result on Facebook

Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued atAdd to Reading List